A new monthly HIV injection regimen has shown to cut treatment failure by nearly half, offering a more manageable alternative for over 126,000 Kenyans struggling with daily antiretroviral pills.

• 22.8% of participants on monthly injections experienced regimen failure compared to 41.2% on daily oral therapy in the LATITUDE trial.
• The trial was presented at the International AIDS Society conference and published in the New England Journal of Medicine.
• Kenyans living with HIV expressed a preference for long-acting therapies over daily oral regimens, according to a study at Kenyatta National Hospital and clinics in Nairobi.